Dupilumab improves lung function in non-exacerbators with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial

Rabe,K. F.,Vogelmeier,C. F.,Bhatt,S. P.,Hanania,N. A.,Bafadhel,M.,Christenson,S. A.,Papi,A.,Singh,D.,Laws,E.,Maloney,J.,Lu,X.,Bauer,D.,Bansal,A.,Robinson,L. B.,Abdulai,R. M.
DOI: https://doi.org/10.1183/13993003.congress-2024.pa4785
IF: 24.3
2024-11-01
European Respiratory Journal
Abstract:BACKGROUND: IL-4 and IL-13 are key and central drivers in type 2 inflammation. Dupilumab, a fully human monoclonal antibody that blocks the shared receptor component for IL-4 and IL-13, reduced exacerbations and improved lung function in the phase 3 BOREAS trial (NCT03930732). This analysis evaluates the effect of dupilumab vs placebo on lung function in a subgroup of patients who did not experience an exacerbation ("non-exacerbators") during BOREAS. METHODS: In BOREAS, patients with COPD with moderate-to-severe airflow limitation and type 2 inflammation (screening blood eosinophils ≥300 cells/μL), on triple therapy, received add-on dupilumab 300 mg q2w or placebo for 52 weeks. Pre-bronchodilator (BD) FEV1 was analyzed at Week 12 in the overall ITT population and in non-exacerbators. RESULTS: In the ITT population, dupilumab (n=468) improved pre-BD FEV1 at Week 12 (least squares [LS] mean difference 83 mL; P <0.0001) compared to placebo (n=471). For non-exacerbators at Week 12, dupilumab (n=286) improved pre-BD FEV1 compared to placebo (n=259) (LS mean difference 85 mL; nominal P =0.0065) (Table) . Dupilumab demonstrated an acceptable safety profile in the ITT population. CONCLUSIONS: Regardless of exacerbations experienced during the 52-Week treatment period, dupilumab improved lung function compared to placebo in non-exacerbators and in the overall ITT population.
respiratory system
What problem does this paper attempt to address?